Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study

Goldman, Jonathan; Garassino, Marina; Chen, Yuanbin; ÖZGÜROĞLU, Mustafa; Dvorkin, Mikhail; Trukhin, Dmytro; Statsenko, Galina; Hotta, Katsuyuki; Ji, Jun; Hochmair, Maximilian; Voitko, Oleksandr; Havel, Libor; Poltoratskiy, Artem; Losonczy, Gyorgy; Reinmuth, Niels; Patel, Nikunj; Laud, Peter; Shire, Norah; Jiang, Haiyi; Paz-Ares, Luis

doi:10.1016/j.lungcan.2020.09.003

Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study

Goldman J. W., Garassino M. C., Chen Y., ÖZGÜROĞLU M., Dvorkin M., Trukhin D., ...More

LUNG CANCER, vol.149, pp.46-52, 2020 (SCI-Expanded)

Publication Type: Article / Article
Volume: 149
Publication Date: 2020
Doi Number: 10.1016/j.lungcan.2020.09.003
Journal Name: LUNG CANCER
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, EMBASE, MEDLINE
Page Numbers: pp.46-52
Istanbul University Affiliated: No

Abstract

Objectives: In the phase III CASPIAN study, first-line durvalumab plus etoposide in combination with either cisplatin or carboplatin (EP) significantly improved overall survival (primary endpoint) versus EP alone in patients with extensive-stage small-cell lung cancer (ES-SCLC) at the interim analysis. Here we report patient-reported outcomes (PROs).